Retatrutide 99% Cas No.2381089-83-2

We specialise in supplying high-purity Retatrutide active pharmaceutical ingredient (API), strictly adhering to internationally advanced pharmaceutical production quality management standards. This product is synthesised and purified using cutting-edge processes, ensuring stable active ingredient content ≥99%. Meeting the stringent requirements for pharmaceutical-grade APIs, it establishes a robust quality foundation for downstream formulation development and production.

We cordially invite partners from all sectors to enquire about collaboration. Leveraging our dependable supply chain and unwavering commitment to quality, let us jointly accelerate the advent of next-generation therapies.

Retatrutide is a novel multi-target incretin-mimetic peptide that exerts broad pharmacological effects by synergistically activating multiple hormone receptors involved in energy metabolism and glucose homeostasis. Its primary actions include: • Glucose-dependent stimulation of insulin secretion from pancreatic beta cells

• Suppression of glucagon secretion from pancreatic alpha cells

• Delay of gastric emptying and enhancement of satiety

• Central appetite suppression through direct action on brain feeding centers

• Potential increase in energy expenditure through specific receptor activation

The innovation of retatrutide lies in its triple receptor agonism, simultaneously and balancedly activating three key receptors:

Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR)

Glucagon-like Peptide-1 Receptor (GLP-1R)

Glucagon Receptor (GCGR)

This synergistic mechanism produces enhanced effects in both glycemic control and weight reduction.

Clinical studies have demonstrated outstanding efficacy:

• Potent weight reduction: Phase II trial data show up to 24.2% mean weight loss after 48-week treatment

• Effective glycemic control: Significant reductions in blood glucose and HbA1c in type 2 diabetes patients

• Comprehensive metabolic benefits: Positive effects on lipid profiles, blood pressure, and other cardiometabolic risk factors

As a pharmaceutical-grade Active Pharmaceutical Ingredient (API), it is primarily used for:

• Development of innovative formulations for obesity, type 2 diabetes, and related metabolic disorders

• Preclinical and clinical research programs

• Regulatory submissions (IND/NDA) worldwide

All information is based on established scientific and clinical data. The product is intended for research and pharmaceutical development purposes only.

Hot Tags: retatrutide 99% cas no.2381089-83-2, China retatrutide 99% cas no.2381089-83-2 manufacturers, suppliers, factory, tranexamic powder